TY - JOUR
T1 - BNT162b2 and mRNA-1273 COVID-19 vaccine effectiveness against the SARS-CoV-2 Delta variant in Qatar
AU - Tang, Patrick
AU - Hasan, Mohammad R
AU - Chemaitelly, Hiam
AU - Yassine, Hadi M
AU - Benslimane, Fatiha M
AU - Al Khatib, Hebah A
AU - AlMukdad, Sawsan
AU - Coyle, Peter
AU - Ayoub, Houssein H
AU - Al Kanaani, Zaina
AU - Al Kuwari, Einas
AU - Jeremijenko, Andrew
AU - Kaleeckal, Anvar Hassan
AU - Latif, Ali Nizar
AU - Shaik, Riyazuddin Mohammad
AU - Abdul Rahim, Hanan F
AU - Nasrallah, Gheyath K
AU - Al Kuwari, Mohamed Ghaith
AU - Al Romaihi, Hamad Eid
AU - Butt, Adeel A
AU - Al-Thani, Mohamed H
AU - Al Khal, Abdullatif
AU - Bertollini, Roberto
AU - Abu-Raddad, Laith J
PY - 2021/12
Y1 - 2021/12
N2 - With the global expansion of the highly transmissible SARS-CoV-2 Delta (B.1.617.2) variant, we conducted a matched test-negative case-control study to assess the real-world effectiveness of COVID-19 messenger RNA vaccines against infection with Delta in Qatar's population. BNT162b2 effectiveness against any, symptomatic or asymptomatic, Delta infection was 45.3% (95% CI, 22.0-61.6%) ≥14 d after the first vaccine dose, but only 51.9% (95% CI, 47.0-56.4%) ≥14 d after the second dose, with 50% of fully vaccinated individuals receiving their second dose before 11 May 2021. Corresponding mRNA-1273 effectiveness ≥14 d after the first or second dose was 73.7% (95% CI, 58.1-83.5%) and 73.1% (95% CI, 67.5-77.8%), respectively. Notably, effectiveness against Delta-induced severe, critical or fatal disease was 93.4% (95% CI, 85.4-97.0%) for BNT162b2 and 96.1% (95% CI, 71.6-99.5%) for mRNA-1273 ≥ 14 d after the second dose. Our findings show robust effectiveness for both BNT162b2 and mRNA-1273 in preventing Delta hospitalization and death in Qatar's population, despite lower effectiveness in preventing infection, particularly for the BNT162b2 vaccine.
AB - With the global expansion of the highly transmissible SARS-CoV-2 Delta (B.1.617.2) variant, we conducted a matched test-negative case-control study to assess the real-world effectiveness of COVID-19 messenger RNA vaccines against infection with Delta in Qatar's population. BNT162b2 effectiveness against any, symptomatic or asymptomatic, Delta infection was 45.3% (95% CI, 22.0-61.6%) ≥14 d after the first vaccine dose, but only 51.9% (95% CI, 47.0-56.4%) ≥14 d after the second dose, with 50% of fully vaccinated individuals receiving their second dose before 11 May 2021. Corresponding mRNA-1273 effectiveness ≥14 d after the first or second dose was 73.7% (95% CI, 58.1-83.5%) and 73.1% (95% CI, 67.5-77.8%), respectively. Notably, effectiveness against Delta-induced severe, critical or fatal disease was 93.4% (95% CI, 85.4-97.0%) for BNT162b2 and 96.1% (95% CI, 71.6-99.5%) for mRNA-1273 ≥ 14 d after the second dose. Our findings show robust effectiveness for both BNT162b2 and mRNA-1273 in preventing Delta hospitalization and death in Qatar's population, despite lower effectiveness in preventing infection, particularly for the BNT162b2 vaccine.
U2 - 10.1038/s41591-021-01583-4
DO - 10.1038/s41591-021-01583-4
M3 - Article
C2 - 34728831
SN - 1078-8956
VL - 27
SP - 2136
EP - 2143
JO - Nature Medicine
JF - Nature Medicine
ER -
